1. Younossi, Z, Anstee, QM, Marietti, M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2018; 15: 11–20.
Google Scholar | Crossref | Medline2. Younossi, ZM, Koenig, AB, Abdelatif, D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64: 73–84.
Google Scholar | Crossref | Medline3. Chalasani, N, Younossi, Z, Lavine, JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018; 67: 328–357.
Google Scholar | Crossref | Medline4. Wattacheril, J. Extrahepatic manifestations of nonalcoholic fatty liver disease. Gastroenterol Clin North Am 2020; 49: 141–149.
Google Scholar | Crossref | Medline5. van der Velde, M, Matsushita, K, Coresh, J, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int 2011; 79: 1341–1352.
Google Scholar | Crossref | Medline6. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017 . Lancet 2020; 395: 709–733.
Google Scholar | Crossref | Medline7. Byrne, CD, Targher, G. NAFLD as a driver of chronic kidney disease. J Hepatol 2020; 72: 785–801.
Google Scholar | Crossref | Medline8. Mantovani, A, Petracca, G, Beatrice, G, et al. Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. Gut. Epub ahead of print 10 December 2020. DOI: 10.1136/gutjnl-2020-323082.
Google Scholar | Crossref9. Paik, J, Golabi, P, Younoszai, Z, et al. Chronic kidney disease is independently associated with increased mortality in patients with nonalcoholic fatty liver disease. Liver Int 2019; 39: 342–352.
Google Scholar | Crossref | Medline10. Singal, AK, Salameh, H, Kuo, YF, et al. Evolving frequency and outcomes of simultaneous liver kidney transplants based on liver disease etiology. Transplantation 2014; 98: 216–221.
Google Scholar | Crossref | Medline11. Singal, AK, Hasanin, M, Kaif, M, et al. Nonalcoholic steatohepatitis is the most rapidly growing indication for simultaneous liver kidney transplantation in the United States. Transplantation 2016; 100: 607–612.
Google Scholar | Crossref | Medline12. Huang, DQ, El-Serag, HB, Loomba, R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2021; 18: 223–238.
Google Scholar | Crossref | Medline13. Zhang, L, Wang, F, Wang, L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet 2012; 379: 815–822.
Google Scholar | Crossref | Medline14. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report . Circulation 2002; 106: 3143–3421.
Google Scholar | Crossref | Medline15. Wong, VW, Adams, LA, de Lédinghen, V, et al. Noninvasive biomarkers in NAFLD and NASH—current progress and future promise. Nat Rev Gastroenterol Hepatol 2018; 15: 461–478.
Google Scholar | Crossref | Medline16. Levey, AS, Bosch, JP, Lewis, JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461–470.
Google Scholar | Crossref | Medline17. Levey, AS, Eckardt, KU, Tsukamoto, Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005; 67: 2089–2100.
Google Scholar | Crossref | Medline18. Chang, Y, Ryu, S, Sung, E, et al. Nonalcoholic fatty liver disease predicts chronic kidney disease in nonhypertensive and nondiabetic Korean men. Metabolism 2008; 57: 569–576.
Google Scholar | Crossref | Medline19. Targher, G, Bertolini, L, Rodella, S, et al. Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis. Clin J Am Soc Nephrol 2010; 5: 2166–2171.
Google Scholar | Crossref | Medline20. Yilmaz, Y, Alahdab, YO, Yonal, O, et al. Microalbuminuria in nondiabetic patients with nonalcoholic fatty liver disease: association with liver fibrosis. Metabolism 2010; 59: 1327–1330.
Google Scholar | Crossref | Medline21. Targher, G, Pichiri, I, Zoppini, G, et al. Increased prevalence of chronic kidney disease in patients with type 1 diabetes and non-alcoholic fatty liver. Diabet Med 2012; 29: 220–226.
Google Scholar | Crossref | Medline22. Sirota, JC, McFann, K, Targher, G, et al. Association between nonalcoholic liver disease and chronic kidney disease: an ultrasound analysis from NHANES 1988-1994. Am J Nephrol 2012; 36: 466–471.
Google Scholar | Crossref | Medline23. Sun, K, Lin, D, Li, F, et al. Fatty liver index, albuminuria and the association with chronic kidney disease: a population-based study in China. BMJ Open 2018; 8: e019097.
Google Scholar | Crossref | Medline24. Liu, HW, Liu, JS, Kuo, KL. Association of nonalcoholic fatty liver and chronic kidney disease: an analysis of 37,825 cases from health checkup center in Taiwan. Ci Ji Yi Xue Za Zhi 2020; 32: 65–69.
Google Scholar25. Musso, G, Gambino, R, Tabibian, JH, et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med 2014; 11: e1001680.
Google Scholar | Crossref | Medline26. Mantovani, A, Zaza, G, Byrne, CD, et al. Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: a systematic review and meta-analysis. Metabolism 2018; 79: 64–76.
Google Scholar | Crossref | Medline27. Yun, HR, Kim, H, Park, JT, et al. Obesity, metabolic abnormality, and progression of CKD. Am J Kidney Dis 2018; 72: 400–410.
Google Scholar | Crossref | Medline28. Chinnadurai, R, Ritchie, J, Green, D, et al. Non-alcoholic fatty liver disease and clinical outcomes in chronic kidney disease. Nephrol Dial Transplant 2019; 34: 449–457.
Google Scholar | Crossref | Medline29. Jang, HR, Kang, D, Sinn, DH, et al. Nonalcoholic fatty liver disease accelerates kidney function decline in patients with chronic kidney disease: a cohort study. Sci Rep 2018; 8: 4718.
Google Scholar | Crossref | Medline30. Targher, G, Byrne, CD. Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease. Nat Rev Nephrol 2017; 13: 297–310.
Google Scholar | Crossref | Medline31. Francque, SM, van der Graaff, D, Kwanten, WJ. Non-alcoholic fatty liver disease and cardiovascular risk: pathophysiological mechanisms and implications. J Hepatol 2016; 65: 425–443.
Google Scholar | Crossref | Medline32. Polyzos, SA, Aronis, KN, Kountouras, J, et al. Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Diabetologia 2016; 59: 30–43.
Google Scholar | Crossref | Medline33. Tesauro, M, Mascali, A, Franzese, O, et al. Chronic kidney disease, obesity, and hypertension: the role of leptin and adiponectin. Int J Hypertens 2012; 2012: 943605.
Google Scholar | Crossref | Medline34. Shabani, P, Emamgholipour, S, Doosti, M. CTRP1 in liver disease. Adv Clin Chem 2017; 79: 1–23.
Google Scholar | Crossref | Medline35. Balmer, ML, Joneli, J, Schoepfer, A, et al. Significance of serum adiponectin levels in patients with chronic liver disease. Clin Sci 2010; 119: 431–436.
Google Scholar | Crossref | Medline36. Silva, TE, Colombo, G, Schiavon, LL. Adiponectin: a multitasking player in the field of liver diseases. Diabetes Metab 2014; 40: 95–107.
Google Scholar | Crossref | Medline37. Kuo, IC, Wu, PH, Lin, HY, et al. The association of adiponectin with metabolic syndrome and clinical outcome in patients with non-diabetic chronic kidney disease. PLoS ONE 2019; 14: e0220158.
Google Scholar | Crossref | Medline38. Docherty, NG, le Roux, CW. Bariatric surgery for the treatment of chronic kidney disease in obesity and type 2 diabetes mellitus. Nat Rev Nephrol 2020; 16: 709–720.
Google Scholar | Crossref | Medline39. Lassailly, G, Caiazzo, R, Ntandja-Wandji, LC, et al. Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis. Gastroenterology 2020; 159: 1290–1301.e5.
Google Scholar | Crossref | Medline40. Orlic, L, Mikolasevic, I, Lukenda, V, et al. Nonalcoholic fatty liver disease and the renin-angiotensin system blockers in the patients with chronic kidney disease. Wien Klin Wochenschr 2015; 127: 355–362.
Google Scholar | Crossref | Medline41. Musso, G, Cassader, M, Cohney, S, et al. Emerging liver-kidney interactions in nonalcoholic fatty liver disease. Trends Mol Med 2015; 21: 645–662.
Google Scholar | Crossref | Medline42. Hirata, T, Tomita, K, Kawai, T, et al. Effect of telmisartan or losartan for treatment of nonalcoholic fatty liver disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY). Int J Endocrinol 2013; 2013: 587140.
Google Scholar | Crossref | Medline43. Musso, G, De Michieli, F, Bongiovanni, D, et al. New pharmacologic agents that target inflammation and fibrosis in nonalcoholic steatohepatitis-related kidney disease. Clin Gastroenterol Hepatol 2017; 15: 972–985.
Google Scholar | Crossref | Medline44. Musso, G, Cassader, M, Cohney, S, et al. Fatty liver and chronic kidney disease: novel mechanistic insights and therapeutic opportunities. Diabetes Care 2016; 39: 1830–1845.
Google Scholar | Crossref | Medline45. Imamura, S, Hirai, K, Hirai, A. The glucagon-like peptide-1 receptor agonist, liraglutide, attenuates the progression of overt diabetic nephropathy in type 2 diabetic patients. Tohoku J Exp Med 2013; 231: 57–61.
Google Scholar | Crossref | Medline46. Groop, PH, Cooper, ME, Perkovic, V, et al. Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care 2013; 36: 3460–3468.
Google Scholar | Crossref | Medline47. Armstrong, MJ, Hull, D, Guo, K, et al. Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. J Hepatol 2016; 64: 399–408.
Google Scholar | Crossref | Medline48. Cui, J, Philo, L, Nguyen, P, et al. Sitagliptin vs. placebo for non-alcoholic fatty liver disease: a randomized controlled trial. J Hepatol 2016; 65: 369–376.
Google Scholar | Crossref | Medline49. Jimenez, LS, Marques, RA, Gestic, MA, et al. Non-invasive markers in non-alcoholic fatty liver disease: reliability is variable according to BMI status. Obes Surg 2021; 31: 3888–3892.
Google Scholar | Crossref | Medline